LOVFF (Cannara Biotech) NonCurrent Deferred Liabilities: $4.83 Mil (As of Feb. 2026)


LOVFF Cannara Biotech Inc LOVFF
80 GF Score
Price $1.31
GF Value $1.17
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Cannara Biotech NonCurrent Deferred Liabilities?

Cannara Biotech LOVFF 80 NonCurrent Deferred Liabilities is $4.83 Mil as of Feb. 2026. GuruFocus rates LOVFF with a GF Score™ of 80/100 and a GF Value™ of $1.17 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Cannara Biotech's non-current deferred liabilities for the quarter that ended in Feb. 2026 was $4.83 Mil.

Cannara Biotech NonCurrent Deferred Liabilities Related Terms

Cannara Biotech NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Cannara Biotech's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cannara Biotech NonCurrent Deferred Liabilities Chart

Cannara Biotech Annual Data
Trend Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial 0.56 0.63 0.64 0.69 2.86

Cannara Biotech Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.76 1.97 2.86 3.89 4.83
LOVFF
80GF Score
Cannara Biotech Inc LOVFF
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $4.83 Mil mean?
Cannara Biotech (LOVFF) has a NonCurrent Deferred Liabilities of $4.83 Mil as of Feb. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Cannara Biotech and its competitors.
Is Cannara Biotech's NonCurrent Deferred Liabilities too high?
Cannara Biotech's current NonCurrent Deferred Liabilities is $4.83 Mil. Overall, Cannara Biotech has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's NonCurrent Deferred Liabilities compare to ZTS and UTHR?
Cannara Biotech's NonCurrent Deferred Liabilities of $4.83 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Drug Manufacturers company?
A good NonCurrent Deferred Liabilities depends on the Drug Manufacturers industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Cannara Biotech and its competitors. Cannara Biotech's current NonCurrent Deferred Liabilities is $4.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (LOVFF) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.17, compared to a current price of $1.31 — trading 12% above its estimated fair value. The current NonCurrent Deferred Liabilities is $4.83 Mil. Cannara Biotech's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Cannara Biotech (LOVFF), the current NonCurrent Deferred Liabilities is $4.83 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cannara Biotech (LOVFF) Overvalued in 2026?

Based on GuruFocus' analysis, Cannara Biotech stock appears to be overvalued. The current stock price of $1.31 is trading 12% above its estimated GF Value™ of $1.17. GuruFocus considers Cannara Biotech to be Modestly Overvalued.

Key valuation signals for LOVFF:

  • NonCurrent Deferred Liabilities: $4.83 Mil
  • GF Value™: $1.17 vs. price of $1.31 (12% above fair value)
  • GF Score™: 80/100 with 5 warning signs

No single metric tells the full story. See the LOVFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cannara Biotech Business Description

Other Exchanges 8CB0:GermanyLOVE:Canada
Address 1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
80GF Score

Get the complete analysis for LOVFF

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.31
Price
$1.17
GF Value